Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to Hold at Zacks Research

Posted by Brenda Bartman on Aug 6th, 2026

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

Several other brokerages have also issued reports on NBIX. Truist Financial increased their price target on Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Monday. Wall Street Zen lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 1st. TD Cowen increased their target price on Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Cantor Fitzgerald lifted their price target on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Royal Bank Of Canada boosted their price target on shares of Neurocrine Biosciences from $195.00 to $198.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.50.

Read Our Latest Research Report on Neurocrine Biosciences

Neurocrine Biosciences Trading Down 2.7%

Shares of NASDAQ NBIX opened at $161.50 on Tuesday. The firm has a market capitalization of $16.42 billion, a P/E ratio of 23.68, a P/E/G ratio of 0.60 and a beta of 0.39. The firm’s 50-day moving average price is $168.32 and its 200-day moving average price is $147.15. Neurocrine Biosciences has a 1-year low of $122.14 and a 1-year high of $186.12.

Insider Buying and Selling

In other news, Director Stephen A. Sherwin sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $165.32, for a total value of $4,133,000.00. Following the transaction, the director owned 15,860 shares in the company, valued at $2,621,975.20. This trade represents a 61.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie V. Norwalk sold 1,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total value of $227,512.50. Following the transaction, the director directly owned 1,588 shares in the company, valued at approximately $289,031.88. The trade was a 44.05% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 395,422 shares of company stock valued at $62,448,693. 4.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds have recently bought and sold shares of the company. DJE Kapital AG bought a new position in shares of Neurocrine Biosciences during the fourth quarter valued at about $28,000. Geneos Wealth Management Inc. grew its position in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. Meeder Asset Management Inc. grew its position in Neurocrine Biosciences by 651.6% in the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after purchasing an additional 202 shares in the last quarter. Basecamp Wealth Advisors LLC increased its stake in Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after buying an additional 204 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC purchased a new stake in Neurocrine Biosciences in the 1st quarter valued at about $33,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.